⚫2156. EXPOSING THE FDA

Three FDA Advisors Resign over Agency's Approval of Shoddy New Alzheimer's Drug

In November 2020, an independent panel slammed Aduhelm, a new Alzheimer's drug just approved by the FDA. When asked if there was supportive evidence for the use of this drug, zero out of the seven panel members said yes.

"The drug, Aduhelm, a monthly infusion priced at $56,000 per year, was approved this week despite weak evidence that it helps patients," reported The New York Times.